FMR LLC

Insider Reports History

Location
Boston, MA
Signature
/s/ Richard Bourgelas, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson.
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by FMR LLC:

Form 4 holding Other*

Flywire Corp

Security class
Common Stock
Shares / value
7,268,490
Estimated value
$135,059,447
Report date
28 May 2021
Price
$18.58
Ownership
F-Prime Capital Partners Tech Fund LP
Form 4 holding Other*

Toast, Inc.

Security class
Class B Common Stock
Shares / value
6,703,780
Estimated value
$113,421,254
Report date
09 Nov 2021
Price
$16.92
Ownership
F-Prime Capital Partners Tech Fund LP
Underlying class
Class A Common Stock
Underlying amount
6,703,780
Form 4 holding Other*

Neumora Therapeutics, Inc.

Security class
Common Stock
Shares / value
5,472,340
Estimated value
$65,558,633
Report date
19 Sep 2023
Price
$11.98
Ownership
F-Prime Capital Partners Life Sciences Fund VII LP
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
4,228,589
Estimated value
$63,306,629
Report date
24 Oct 2022
Price
$14.97
Ownership
Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
4,124,375
Estimated value
$61,746,431
Report date
24 Oct 2022
Price
$14.97
Ownership
F-Prime Capital Partners Life Sciences Fund VI LP
Form 4 holding Other*, 10%+ Owner

Beam Therapeutics Inc.

Security class
Common Stock
Shares / value
1,139,443
Estimated value
$27,654,281
Report date
27 Oct 2025
Price
$24.27
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Form 4 holding Other*, 10%+ Owner

Structure Therapeutics Inc.

Security class
American Depositary Shares
Shares / value
1,515,558
Estimated value
$27,083,021
Report date
14 Apr 2026
Price
$17.87
Ownership
Shares held by persons and entities whose shares are subject to reporting by the undersigned
Underlying class
Ordinary Shares
Underlying amount
4,625,604
Form 4 holding Other*, 10%+ Owner

Beam Therapeutics Inc.

Security class
Common Stock
Shares / value
841,231
Estimated value
$20,416,676
Report date
27 Oct 2025
Price
$24.27
Ownership
Shares held by persons and entities whose shares are subject to reporting by the undersigned.
Form 4 holding Other*

Bicara Therapeutics Inc.

Security class
Common Stock
Shares / value
1,115,333
Estimated value
$14,770,801
Report date
16 Sep 2024
Price
$13.24
Ownership
F-Prime Capital Partners Life Sciences Fund VII LP
Form 4 holding Other*, 10%+ Owner

Sana Biotechnology, Inc.

Security class
Common Stock
Shares / value
4,541,511
Estimated value
$7,493,493
Report date
08 Jan 2025
Price
$1.65
Ownership
F-Prime Capital Partners Life Sciences Fund VI LP
Form 4 holding Other*

Verve Therapeutics, Inc.

Security class
Common Stock
Shares / value
570,729
Estimated value
$5,707,290
Report date
26 Jul 2022
Price
$10.00
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Form 4 holding Other*

Caribou Biosciences, Inc.

Security class
Common Stock
Shares / value
1,840,937
Estimated value
$5,449,174
Report date
27 Jul 2021
Price
$2.96
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Form 4 holding Other*, 10%+ Owner

Structure Therapeutics Inc.

Security class
American Depositary Shares
Shares / value
58,864
Estimated value
$4,832,734
Report date
15 Jan 2026
Price
$82.10
Ownership
F-Prime Capital Partners Life Sciences Fund VI LP LP
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Other*

Caribou Biosciences, Inc.

Security class
Common Stock
Shares / value
1,464,775
Estimated value
$4,335,734
Report date
27 Jul 2021
Price
$2.96
Ownership
Impresa Fund III Limited Partnership
Form 4 holding Other*, 10%+ Owner

Structure Therapeutics Inc.

Security class
American Depositary Shares
Shares / value
32,171
Estimated value
$1,771,656
Report date
14 Apr 2026
Price
$55.07
Ownership
F-Prime Capital Partners Life Sciences Fund VI LP
Underlying class
Ordinary Shares
Underlying amount
48,249
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
109,982
Estimated value
$1,646,552
Report date
24 Oct 2022
Price
$14.97
Ownership
F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Common Stock
Shares / value
1,530,990
Estimated value
$1,270,722
Report date
26 Oct 2021
Price
$0.8300
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Form 4 holding Other*

Neumora Therapeutics, Inc.

Security class
Common Stock
Shares / value
63,724
Estimated value
$763,414
Report date
19 Sep 2023
Price
$11.98
Ownership
F-Prime Inc.
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Common Stock
Shares / value
372,215
Estimated value
$308,938
Report date
26 Oct 2021
Price
$0.8300
Ownership
Impresa Fund III Limited Partnership
Form 4 holding Other*, 10%+ Owner

Structure Therapeutics Inc.

Security class
American Depositary Shares
Shares / value
2,736
Estimated value
$150,671
Report date
14 Apr 2026
Price
$55.07
Ownership
F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Underlying class
Ordinary Shares
Underlying amount
4,095
Form 4 holding Other*, 10%+ Owner

Rallybio Corp

Security class
Common Stock
Shares / value
211,798
Estimated value
$122,842
Report date
04 Mar 2026
Price
$0.5800
Ownership
F-Prime Capital Partners Life Sciences Fund VI LP
Form 4 holding Other*

Caribou Biosciences, Inc.

Security class
Common Stock
Shares / value
17,572
Estimated value
$52,013
Report date
27 Jul 2021
Price
$2.96
Ownership
F-Prime Capital Partners Healthcare Advisors Fund IV LP
Form 4 holding Other*

Fidelity Private Credit Fund

Security class
Class D Common Shares of Beneficial Interest
Shares / value
398
Estimated value
$10,163
Report date
29 Jan 2024
Price
$25.54
Ownership
FMR Capital Inc.
Form 4 holding Other*

Fidelity Private Credit Fund

Security class
Class S Common Shares of Beneficial Interest
Shares / value
398
Estimated value
$10,153
Report date
29 Jan 2024
Price
$25.54
Ownership
FMR Capital Inc.
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Common Stock
Shares / value
4,465
Estimated value
$3,706
Report date
26 Oct 2021
Price
$0.8300
Ownership
F-Prime Capital Partners Healthcare Advisors Fund IV LP
Form 4 holding Other*, 10%+ Owner

Sana Biotechnology, Inc.

Security class
Common Stock
Shares / value
61
Estimated value
$101
Report date
08 Jan 2025
Price
$1.65
Ownership
FMR Capital, Inc.
Form 4 holding Other*, 10%+ Owner

Metsera, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
13 Nov 2025
Price
$52.51
Ownership
Shares held by persons and entities whose shares are subject to reporting by the undersigned.
Form 4 holding Other*, 10%+ Owner

Structure Therapeutics Inc.

Security class
American Depositary Shares
Shares / value
0
Estimated value
$0
Report date
06 Feb 2025
Price
$30.54
Ownership
FIMM, LLC
Underlying class
Ordinary Shares
Underlying amount
123
Form 4 holding Other*, 10%+ Owner

Avalyn Pharma Inc.

Security class
Common Stock
Shares / value
2,284,535
Estimated value
Report date
01 May 2026
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Form 4 holding Other*

Fidelity Private Credit Fund

Security class
Class I Common Shares of Beneficial Interest
Shares / value
1,280,002
Estimated value
Report date
29 Jan 2024
Price
Ownership
Direct
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Common Stock
Shares / value
832,652
Estimated value
Report date
09 Jan 2024
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Form 4 holding Other*

Fidelity Private Credit Fund

Security class
Class I Common Shares of Beneficial Interest
Shares / value
352,360
Estimated value
Report date
29 Jan 2024
Price
Ownership
Fidelity Multi-Strategy Credit Fund
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Common Stock
Shares / value
296,396
Estimated value
Report date
09 Jan 2024
Price
Ownership
Impresa Fund III Limited Partnership
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Common Stock
Shares / value
4,939
Estimated value
Report date
09 Jan 2024
Price
Ownership
F-Prime Capital Partners Healthcare Advisors Fund V LP
Form 4 holding Other*

Fidelity Private Credit Fund

Security class
Class I Common Shares of Beneficial Interest
Shares / value
86
Estimated value
Report date
29 Jan 2024
Price
Ownership
FMR Capital Inc.
Form 4 holding Other*, 10%+ Owner

Avalyn Pharma Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
01 May 2026
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*, 10%+ Owner

Avalyn Pharma Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
01 May 2026
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*, 10%+ Owner

Avalyn Pharma Inc.

Security class
Series C-1 Preferred Stock
Shares / value
0
Estimated value
Report date
01 May 2026
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*, 10%+ Owner

Avalyn Pharma Inc.

Security class
Series C-2 Preferred Stock
Shares / value
0
Estimated value
Report date
01 May 2026
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*, 10%+ Owner

Avalyn Pharma Inc.

Security class
Series D Preferred Stock
Shares / value
0
Estimated value
Report date
01 May 2026
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Bicara Therapeutics Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
16 Sep 2024
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VII LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Bicara Therapeutics Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
16 Sep 2024
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VII LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Bicara Therapeutics Inc.

Security class
Series Seed Preferred Stock
Shares / value
0
Estimated value
Report date
16 Sep 2024
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VII LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Caribou Biosciences, Inc.

Security class
Series A-1 Preferred Stock
Shares / value
0
Estimated value
Report date
27 Jul 2021
Price
Ownership
F-Prime Capital Partners Healthcare Advisors Fund IV LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Caribou Biosciences, Inc.

Security class
Series A-1 Preferred Stock
Shares / value
0
Estimated value
Report date
27 Jul 2021
Price
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Caribou Biosciences, Inc.

Security class
Series A-1 Preferred Stock
Shares / value
0
Estimated value
Report date
27 Jul 2021
Price
Ownership
Impresa Fund III Limited Partnership
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Caribou Biosciences, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
27 Jul 2021
Price
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Flywire Corp

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
28 May 2021
Price
Ownership
F-Prime Capital Partners Tech Fund LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Flywire Corp

Security class
Series B-1 NV Preferred Stock
Shares / value
0
Estimated value
Report date
28 May 2021
Price
Ownership
F-Prime Capital Partners Tech Fund LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Flywire Corp

Security class
Series B-1 Preferred Stock
Shares / value
0
Estimated value
Report date
28 May 2021
Price
Ownership
F-Prime Capital Partners Tech Fund LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Flywire Corp

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
28 May 2021
Price
Ownership
F-Prime Capital Partners Tech Fund LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Flywire Corp

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
28 May 2021
Price
Ownership
F-Prime Capital Partners Tech Fund LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*, 10%+ Owner

Metsera, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
03 Feb 2025
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VIII LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*, 10%+ Owner

Metsera, Inc.

Security class
Series Seed Preferred Stock
Shares / value
0
Estimated value
Report date
03 Feb 2025
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VIII LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Neumora Therapeutics, Inc.

Security class
Series A-2 Preferred Stock
Shares / value
0
Estimated value
Report date
19 Sep 2023
Price
Ownership
FBRI LLC
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Neumora Therapeutics, Inc.

Security class
Series A-2 Preferred Stock
Shares / value
0
Estimated value
Report date
19 Sep 2023
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VII LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Neumora Therapeutics, Inc.

Security class
Series A-2 Preferred Stock
Shares / value
0
Estimated value
Report date
19 Sep 2023
Price
Ownership
F-Prime Inc.
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Neumora Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
19 Sep 2023
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VII LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Series A Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
24 Oct 2022
Price
Ownership
Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Series A Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
24 Oct 2022
Price
Ownership
F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Series A Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
24 Oct 2022
Price
Ownership
F-Prime Capital Partners Life Sciences Fund VI LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Series B Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
24 Oct 2022
Price
Ownership
Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Prime Medicine, Inc.

Security class
Series B Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
24 Oct 2022
Price
Ownership
F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Series B-1 Preferred Stock
Shares / value
0
Estimated value
Report date
25 Jul 2023
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Series B-2 Preferred Stock
Shares / value
0
Estimated value
Report date
25 Jul 2023
Price
Ownership
F-Prime Capital Partners Healthcare Advisors Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Series B-2 Preferred Stock
Shares / value
0
Estimated value
Report date
25 Jul 2023
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Series B-2 Preferred Stock
Shares / value
0
Estimated value
Report date
25 Jul 2023
Price
Ownership
Impresa Fund III Limited Partnership
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
25 Jul 2023
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Turnstone Biologics Corp.

Security class
Series D Preferred Stock
Shares / value
0
Estimated value
Report date
25 Jul 2023
Price
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Series A-1 Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2021
Price
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2021
Price
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2021
Price
Ownership
F-Prime Capital Partners Healthcare Advisors Fund IV LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2021
Price
Ownership
F-Prime Capital Partners Healthcare Fund IV LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Xilio Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2021
Price
Ownership
Impresa Fund III Limited Partnership
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by FMR LLC

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .